• Non ci sono risultati.

Nuovi dati

N/A
N/A
Info
Scarica
Protected

Academic year: 2022

Condividi "Nuovi dati"

Copied!
56
0
0

Caricamento.... (Visualizza il testo completo ora)

Scarica adesso ( 56 pagine )

Testo completo

(1)

NUOVI DATI

Lucia Mentuccia

UOC Oncologia ASL Frosinone

SESSIONE: BREAST

(2)

Early Breast Cancer

• Integrating PI3K and CDK 4-6 inhibitors in the neoadjuvant treatment of ER + EBC LORELEI STUDY & NEOPAL STUDY

• Dual endocrine blockade as adjuvant therapy in ER+ EBC GEICAM 2006-10 TRIAL

• Escalating adjuvant therapy in HER2+ EBC EXTENET TRIAL

(3)

Early Breast Cancer

• Integrating PI3K and CDK 4-6 inhibitors in the neoadjuvant treatment of ER + EBC LORELEI STUDY & NEOPAL STUDY

• Dual endocrine blockade as adjuvant therapy in ER+ EBC GEICAM 2006-10 TRIAL

• Escalating adjuvant therapy in HER2+ EBC EXTENET TRIAL

(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)

Early Breast Cancer

• Integrating PI3K and CDK 4-6 inhibitors in the neoadjuvant treatment of ER + EBC LORELEI STUDY & NEOPAL STUDY

• Dual endocrine blockade as adjuvant therapy in ER+ EBC GEICAM 2006-10 TRIAL

• Escalating adjuvant therapy in HER2+ EBC EXTENET TRIAL

(22)
(23)
(24)
(25)

Median FU =6.3 yrs

(26)

Median FU =6.3 yrs

(27)
(28)

Early Breast Cancer

• Integrating PI3K and CDK 4-6 inhibitors in the neoadjuvant treatment of ER + EBC LORELEI STUDY & NEOPAL STUDY

• Dual endocrine blockade as adjuvant therapy in ER+ EBC GEICAM 2006-10 TRIAL

• Escalating adjuvant therapy in HER2+ EBC EXTENET TRIAL

(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)

Metastatic Breast Cancer

• Predicting immunogenenicity in breast cancer KEYNOTE - 086 STUDY

• Consistent benefit across studies –class effect of CDK4/6 inhibitors MONARCH 3 TRIAL

(37)

Metastatic Breast Cancer

• Predicting immunogenenicity in breast cancer KEYNOTE - 086 STUDY

• Consistent benefit across studies –class effect of CDK4/6 inhibitors MONARCH 3 TRIAL

(38)
(39)
(40)
(41)
(42)
(43)
(44)

Metastatic Breast Cancer

• Predicting immunogenenicity in breast cancer KEYNOTE - 086 STUDY

• Consistent benefit across studies –class effect of CDK4/6 inhibitors MONARCH 3 TRIAL

(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)

Riferimenti

Scarica adesso ( PDF - 56 pagine - 6.70 MB )

Documenti correlati

Landscape of circulating tumour DNA in metastatic breast cancer

Similarly, a signi ficant finding was observed when analysing the number of detected alterations in ctDNA compared with sites of disease (Mann Whitney U test, P <0.0001) ( Fig. 4

Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone- receptor-positive, HER2-negative metastatic breast cancer that pro- gressed on

Identification of HSP90 inhibitors as a novel class of senolytics

To determine whether the senolytic effect of the HSP90 inhibitors is cell-type or species specific, we tested 17-DMAG on senescent cultures of primary murine mesenchymal stem

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Our research question is whether relevant differences exist in long-term outcomes of patients with concordant HER2 status between the primary tumor and its secondary lesion/s

Biopatch Class Effect

Key elements for the choice of antimicrobial dressings to prevent infections associated with intravascular catheters include the ability of the antimicrobial agent (1) to be

NATO in the mid-1960s: the view of Secretary-general Manlio Brosio

In order to prevent a crisis between the fourteen remaining NATO members, who wanted the alliance to promote and control the whole process of détente, and France, which did not

The role of big data and cognitive computing in the learning process

In addition, if we all agree that big open data will be the bulk of the forthcoming social and technological development scenario, it is worth noticing that this introduces the need

Class 1 Class 1 3 Class Unknown 3 Class

Possibly different inactive ingredients (excipients, stabilizers, dyes, flavouring agents…).. Same salt, ester, complex Different salt,